UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Driving Opposing Behaviors with Ensembles of Piriform Neurons

Cell, 2011-09, Vol.146 (6), p.1004-1015

2011

Volltextzugriff (PDF)

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

Cancer Immunology, Immunotherapy, 2013-12, Vol.62 (12), p.1841-1849

2013

Volltextzugriff (PDF)

Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy

Bone marrow transplantation (Basingstoke), 2024-02, Vol.59 (2), p.211-216

2024

Volltextzugriff (PDF)

Role of bridging therapy during chimeric antigen receptor T cell therapy

EJHaem, 2022-01, Vol.3 (S1), p.39-45

2022

Volltextzugriff (PDF)

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.131-142

2024

Volltextzugriff (PDF)

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Blood advances, 2023-09, Vol.7 (17), p.4765-4772

2023

Volltextzugriff (PDF)

Artificial intelligence modelling to assess the risk of cardiovascular disease in oncology patients

European heart journal. Digital health, 2023-08, Vol.4 (4), p.302-315

2023

Volltextzugriff (PDF)

Efficacy of a novel journal club series at an academic hematology/oncology fellowship program

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.11027-11027

2022

Volltextzugriff (PDF)

The Evolving Role of Bridging Therapy during CAR-T Therapy

Clinical hematology international, 2024-07, Vol.6 (3), p.9-16

2024

Volltextzugriff (PDF)

BMI Is Not Associated with Toxicity to High Dose Methotrexate: A Single Institution Retrospective Study of 147 Patients

Blood, 2020-11, Vol.136 (Supplement 1), p.42-42

2020

Volltextzugriff (PDF)

Patterns of Use and Impact of Post-Referral and Bridging Therapy on Outcomes in Patients Undergoing CAR T-Cell Therapy for B-Cell Lymphoma: A Single-Center Analysis

Blood, 2023-11, Vol.142 (Supplement 1), p.6940-6940

2023

Volltextzugriff (PDF)

Impact of Time from Referral to Treatment on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma: An Intention to Treat Analysis

Blood, 2023-11, Vol.142 (Supplement 1), p.5080-5080

2023

Volltextzugriff (PDF)

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Blood, 2023-11, Vol.142 (Supplement 1), p.3778-3778

2023

Volltextzugriff (PDF)

Overview of approved CAR-T products and utility in clinical practice

Clinical hematology international, 2024-10, Vol.6 (4), p.93-99

2024

Volltextzugriff (PDF)

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Blood, 2022-11, Vol.140 (Supplement 1), p.10971-10973

2022

Volltextzugriff (PDF)

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.366-368

2022

Volltextzugriff (PDF)

Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood, 2022-11, Vol.140 (Supplement 1), p.10396-10398

2022

Volltextzugriff (PDF)

T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma

Blood advances, 2020-10, Vol.4 (19), p.4640-4647

2020

Volltextzugriff (PDF)

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.165-165

2021

Volltextzugriff (PDF)

Lenalidomide demonstrates clinical activity in anaplastic lymphoma kinase-positive large B-cell lymphoma

BMJ case reports, 2020-08, Vol.13 (8), p.e235578

2020

Volltextzugriff (PDF)

Interim Analysis of Prospective Clinical Trial of Outpatient Administration of Axicabtagene Ciloleucel in High-Grade B Cell Lymphoma

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S220-S221

2024

Volltextzugriff (PDF)

Current and Future Immunotherapeutic Approaches to Multiple Myeloma Therapy

International journal of hematologic oncology, 2015-03, Vol.4 (1), p.23-31

2015

Volltextzugriff (PDF)

The Impact of Telemedicine and Wearable Devices in Improving the Safety Profile of Outpatient Chimeric Antigen Receptor T-Cell (CAR-T) Therapies: A Case-Control Study

Transplantation and cellular therapy, 2023-02, Vol.29 (2), p.S157-S158

2023

Volltextzugriff (PDF)

Chimeric Antigen Receptor T-Cell Therapy Yields Similar Outcomes in Patients with and without Cytokine Release Syndrome

Transplantation and cellular therapy, 2023-02, Vol.29 (2), p.S38-S40

2023

Volltextzugriff (PDF)

201 - The Impact of Telemedicine and Wearable Devices in Improving the Safety Profile of Outpatient Chimeric Antigen Receptor T-Cell (CAR-T) Therapies: A Case-Control Study

Transplantation and cellular therapy, 2023-02, Vol.29 (2), p.S157-S158

2023

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Driving Opposing Behaviors with Ensembles of Piriform Neurons

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy

Role of bridging therapy during chimeric antigen receptor T cell therapy

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Artificial intelligence modelling to assess the risk of cardiovascular disease in oncology patients

Efficacy of a novel journal club series at an academic hematology/oncology fellowship program

The Evolving Role of Bridging Therapy during CAR-T Therapy

BMI Is Not Associated with Toxicity to High Dose Methotrexate: A Single Institution Retrospective Study of 147 Patients

Patterns of Use and Impact of Post-Referral and Bridging Therapy on Outcomes in Patients Undergoing CAR T-Cell Therapy for B-Cell Lymphoma: A Single-Center Analysis

Impact of Time from Referral to Treatment on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma: An Intention to Treat Analysis

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Overview of approved CAR-T products and utility in clinical practice

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Lenalidomide demonstrates clinical activity in anaplastic lymphoma kinase-positive large B-cell lymphoma

Interim Analysis of Prospective Clinical Trial of Outpatient Administration of Axicabtagene Ciloleucel in High-Grade B Cell Lymphoma

Current and Future Immunotherapeutic Approaches to Multiple Myeloma Therapy

The Impact of Telemedicine and Wearable Devices in Improving the Safety Profile of Outpatient Chimeric Antigen Receptor T-Cell (CAR-T) Therapies: A Case-Control Study

Chimeric Antigen Receptor T-Cell Therapy Yields Similar Outcomes in Patients with and without Cytokine Release Syndrome

201 - The Impact of Telemedicine and Wearable Devices in Improving the Safety Profile of Outpatient Chimeric Antigen Receptor T-Cell (CAR-T) Therapies: A Case-Control Study

Suchergebnisse filtern